European Biopharmaceutical Review |
 |
|
|
|
|
 |
| |
|
|
|
Outsourcing
Boon or Bane
With manufacturing costs on the rise, Aiswariya Chidambaram at Frost & Sullivan demonstrates how outsourcing has become a strategic move for pharmaceutical and biotech companies.
|
|
|
Emerging Markets
Made to Measure
Vijaya Vulapalli at GBI Research investigates how emerging Asian markets are gaining on their US and European competitors by acquiring outsourcing contracts from Big Pharma.
|
|
|
|
|
Biodevelopment
Body of Evidence
The cancer treatment landscape has found a powerful new approach in the form of Biological Response Modifiers. Alex Casta at Biocat explains how this technique could generate gene and cell therapies, leading to truly personalised medicine.
|
|
|
Rare Disease Sustainability
The Price of Value
Tony Hall at Cudos examines the orphan drug sector and the high cost prices that rare diseases may incur. Do they put investors off?
|
|
|
Collaboration in Regenerative Medicine
The Networking Game
A possible answer to the increasing cost of healthcare and diminishing resources in the pharma industry may be rectified through Regenerative Medicine, suggest Frank-Roman Lauter, Sylvie Ponchaut, Greg A Bonfiglio, Chris Mason and Boo Edgar.
|
|
|
Developability
Surviving the Valley of Death
Developability looks to become a crucial area of attention in the biopharmaceutical sector. Jesús Zonda at Lonza Biologics explains how increasing drug development costs can be avoided simply by choosing suitable candidates with specific qualities.
|
|
|
|
Drug Production
An Age of Orphans
Small markets with unmet medical needs are becoming a lucrative area, explains G Steven Burrill at Burrill & Company. Regulations and new developments are driving innovation forward as pharma makes the transition from blockbuster to niche drugs.
|
|
|
RNA-Based Therapeutics
The Rise of the Nano
Anti-tumour treatments with nanoparticles in the delivery of siRNA can claim a signifi cant amount of success, but there are still a number of obstacles to tackle, as Surendra Nimesh at Health Canada illustrates.
|
|
|
ADME-Tox Screening
Gene Expression Analysis
In order to regulate pricing in the drug development process, eradicating incompatible compounds at an earlier stage is needed. Determining their ADME-Tox summary could be the answer, explains Jari Rautio at Plexpress.
|
|
|
Antibiotic Development
One Bug, One Drug
David Livermore and John Wain at Norwich Research Park discuss the current challenges facing antibiotic researchers as they track bacteria composition in the human body.
|
|
|
|
Chinese Healthcare
One Country, Two Markets
Zhihao Yu at Lux Research assesses the current state of China, where social class segregation is dividing the healthcare system into two distinct markets. How will the Chinese government tackle this challenge?
|
|
|
|
|
Biomanufacturing
The Big Squeeze
Eric S Langer at BioPlan Associates considers the recent progression of biotechnological facilities, and presents the challenges they may face in years to come.
|
|
|
|
Biologic Cancer Therapy
Therapy for the Soul
In order for cancer solutions to advance, a closer look at the design of clinical trials needs to be addressed, says David Edwards of Cancer Research UK.
|
|
|
Cancer Research
Where NGS Leads
Modern genomic tools have transformed biological and clinical research, argues Dr Fang Tian at ATCC. In particular, Next Generation Sequencing appears to provide a higher calibre analysis of gene expression, which can enhance our understanding of the cancer genome.
|
|
|
Haematology and Oncology
A Complex Puzzle
Daniel Mazzolenis and Swapnil Pandey at INC Research explore the complicated field of haematology and oncology, describing how the peculiarities of these biologic studies could make the difference between the success or failure of a specific project.
|
|
|
|
Industry Interview
People Potential
Sean Russell of Premier Research discusses his career motivation and looks forward to the future of pharma.
|
|
|
Industry Interview
Providing Solutions
Shayesteh Fürst-Ladani of SFL Regulatory Affairs & Scientific Communication Ltd provides advice for budding entrepreneurs and reveals her upcoming goals.
|
|
|
|
|
|
